Efficacy of first‐line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS , MET , FGFR , RET , BRAF , and HER2 alterations

BACKGROUND: In patients with non‐small cell lung cancer (NSCLC) harboring driver alterations, the efficacy of immune checkpoint inhibitors (ICIs) remains uncertain. Our study aimed to examine the first‐line ICI efficacy in patients with NSCLC harboring KRAS, MET, FGFR, RET, BRAF, and HER2 alteration...

Descripción completa

Detalles Bibliográficos
Autores principales: Uehara, Yuji, Watanabe, Kageaki, Hakozaki, Taiki, Yomota, Makiko, Hosomi, Yukio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161348/
https://www.ncbi.nlm.nih.gov/pubmed/35491960
http://dx.doi.org/10.1111/1759-7714.14448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161348/
https://www.ncbi.nlm.nih.gov/pubmed/35491960
http://dx.doi.org/10.1111/1759-7714.14448

Ejemplares similares